H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With "Buy" Rating and $19 PT

With strong three-month performance and significant upside potential, Acrivon Therapeutics, Inc. (NASDAQ:ACRV) secures a spot on our list of the 12 hot penny stocks to invest in right now.

On November 25, 2025, Acrivon Therapeutics, Inc. (NASDAQ:ACRV) saw H.C. Wainwright’s Emily Bodnar initiate coverage with a “Buy” rating and a $19 price target. The analyst’s bullish rating reflected the company’s strong outlook driven by robust developments in its pipeline, especially the ACR-368 Phase 2b trial. With the inclusion of a third cohort, enrollment and overall response rate are expected to increase, particularly among patients who are less heavily pretreated. Furthermore, this cohort, which does not require a pretreatment biopsy, along with the use of ultra-low-dose gemcitabine, is expected to broaden access to treatment, thereby improving the company’s market positioning.

Meanwhile, on November 13, Acrivon Therapeutics, Inc. (NASDAQ:ACRV) announced its Q3 2025 results, where it reported a net loss of $18.2 million, an improvement compared to $22.4 million a year earlier. The company’s strategic focus on endometrial cancer was evident from its R&D expenses, which fell from $18.9 million a year ago to $13.6 million. Moreover, the company closed the quarter with $134.4 million in cash reserves, which will likely fund operations into Q2 2027. The quarter also marked the continued advancement of the ACR-368 trial for endometrial cancer, while progressing the ACR-2316 Phase 1 trial, which showed early signs of clinical activity and tumor shrinkage.

Acrivon Therapeutics, Inc. (NASDAQ:ACRV), a clinical-stage biopharmaceutical company, develops precision medicines using its Generative Phosphoproteomics AP3 platform to design targeted treatments.

While we acknowledge the potential of ACRV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Small-Cap Biotech Stocks to Buy According to Analysts and 11 Overlooked Tech Stocks to Invest In.

Disclosure: None.